According to filings with the U.S. Securities and Exchange Commission, Tellus Therapeutics is raising $35,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jason Kralic played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Tellus Therapeutics
Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. Tellus lead candidate, TT-20, induces regeneration of myelin-producing oligodendrocytes, reverses white matter injury in an animal models of perinatal brain injury and multiple sclerosis and is pursuing a novel regulatory path to evaluate safety and efficacy in newborns with brain injury. Preterm infants are our most vulnerable patient population and are at risk for a variety of injuries that can alter normal development. During the neonatal period, the preterm infant brain is in its early stages of development. Factors influencing brain development during this time can have lifelong impacts on a child’s neurologic outcome. Specifically, neonatal events causing inflammation or oxygen deprivation can result in white matter injury (WMI) to the brain, resulting in neurodevelopmental deficits impacting a child’s motor and cognitive abilities. There are currently no treatment options for these infants. Tellus Therapeutics is developing TT-20 for preterm infants at risk for WMI, with the goal of improving neurodevelopmental outcomes for all patients treated.

To learn more about Tellus Therapeutics, visit http://www.tellustherapeutics.com/

Contact:
Jason Kralic, Chief Executive Officer
919-491-4995
https://www.linkedin.com/in/jasonkralic/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.